Eskayef has entered a technology transfer arrangement with Novo Nordisk, which supplies roughly 40 percent of Bangladesh's insulin demand, marking a shift from reliance on imports.

Diabetes is a global epidemic, and this epidemic is rising faster in developing countries like Bangladesh than in developed ones.

Scientists finally reveal a complete picture of the areas that the immune system attacks to cause type 1 diabetes.